New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 23, 2013
15:54 EDTJNJ, CG, BX, DHRCarlyle in lead to buy J&J ortho clinical diagnostics unit, Reuters says
Johnson & Johnson (JNJ) currently views a bid from Carlyle Group (CG) for its ortho clinical diagnostics unit as superior to a rival bid from Blackstone Group (BX) in partnership with conglomerate Danaher (DHR), three people familiar with the matter said, according to Reuters, which added that the price of Carlyle's offer could not be learned. Reference Link
News For JNJ;CG;BX;DHR From The Last 14 Days
Check below for free stories on JNJ;CG;BX;DHR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 29, 2014
15:13 EDTBXQuirky drops out of bidding to buy appliance unit from GE, Bloomberg says
Subscribe for More Information
August 28, 2014
17:42 EDTJNJJ&J begins sales process for its medical device unit Cordis, WSJ says
Subscribe for More Information
15:30 EDTBXBlackstone planning NYC tower sale for over $2B, Bloomberg says
Blackstone (BX) has hired Eastdil Secured to market 1095 Avenue of the Americas, which will soon be the headquarters of Verizon (VZ), and the NYC building may sell for about $2.25B, according to Bloomberg, citing people familiar with the matter. Reference Link
15:25 EDTBXBlackstone planning NYC tower sale for over $2B, Bloomberg says
Subscribe for More Information
August 27, 2014
06:39 EDTCGCarlyle, Vanke in advanced discussions for mall acquisitions, Reuters says
Subscribe for More Information
August 25, 2014
08:27 EDTJNJJanssen Affiliate Cilag acquires Covagen, terms not disclosed
Subscribe for More Information
07:03 EDTJNJVIVUS acquires patents from Janssen Pharmaceuticals
VIVUS (VVUS) announced the acquisition of a group of patents from Janssen Pharmaceuticals (JNJ) covering uses of topiramate as monotherapy and in combination with other pharmaceutical agents to treat a variety of medical conditions. Janssen has agreed to dismiss the lawsuit it brought against VIVUS on August 22, 2014 in the U.S. District Court for the District of Delaware. VIVUS will pay a one-time upfront fee and a royalty to Janssen on Qsymia product sales for an assignment of these topiramate-related patents owned by Janssen. VIVUS has an option to buy out the royalty for a predetermined amount.
August 22, 2014
06:54 EDTBXBlackstone using loophole in European loan rules, Reuters says
Subscribe for More Information
06:42 EDTBXBlackstone in discussions to back China-based fund, Bloomberg says
Blackstone (BX) is in discussions to possibly back Hong Kong-based distressed fund, Arkkan Capital Management, which was founded by the former global leader of Goldman Sachs' (GS) special situations division Jason Brown, according to Bloomberg, citing two people with knowledge of the matter. Reference Link
August 21, 2014
05:42 EDTJNJIllumina announces strategic partnership with AstraZeneca, Sanofi, Janssen
Illumina (ILMN) announced it has formed collaborative partnerships with leading pharmaceutical companies to develop a universal next-generation sequencing, or NGS,-based oncology test system. The system will be used for clinical trials of targeted cancer therapies with a goal of developing and commercializing a multi-gene panel for therapeutic selection, resulting in a more comprehensive tool for precision medicine. Initial strategic partners include AstraZeneca (AZN), Janssen Biotech, a Johnson & Johnson (JNJ) company, and Sanofi (SNY). Illumina is working with the strategic partners to develop assays that detect and measure multiple variants simultaneously to support partners’ clinical trials, with the objectives of securing regulatory agency approvals and test commercialization. In parallel, Illumina is working with key thought leaders to set standards for NGS-based assays in routine clinical oncology practice, as well as to define regulatory frameworks to enable this new testing paradigm. Together, Illumina and its strategic partners aim to transition from single-analyte companion diagnostics to panel-based assays that select for “companion therapeutics.”
August 18, 2014
11:41 EDTJNJCubist rises after report sparks takeover interest speculation
Subscribe for More Information
06:43 EDTBXReport says Blackstone, TPG near Kensington takeover deal, Sky News says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use